Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | RORA | P35398 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | RORB | Q92753 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909959 | 0.89 | PGR (0.53) | PGRCNR2ALDH1A1KDM4EGAA | |
| SCHEMBL6421284 | 0.89 | CNR2 (0.57) | PGRRORARORCRORBTDP1 | |
| SCHEMBL25316072 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL28002722 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL8862370 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL25318908 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL30484776 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL30484777 | 0.87 | CNR2 (0.56) | PGRRORARORCRORBTDP1 | |
| SCHEMBL4621924 | 0.86 | ALDH1A1 (0.59) | PGRL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL27369455 | 0.85 | TSHR (0.57) | PGRRORARORCRORBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8063070-B2 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-11-22 | — | — | US | disclosed |
| US-7790750-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-7205410-B2 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A | 2007-02-15 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | HRH2, HRH4, GIPR | PGR 1986/4885RORA 570/4885RORC 441/4885 |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, SLC10A2, HRH4 | PGR 4161/4885RORA 4153/4885RORC 3521/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | PGR 4012/4885RORA 4339/4885RORC 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.